ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026. The company will host a conference call on March 5, 2026 at 9:00 AM ET to review results.
Dial-in numbers, replay access (code #2017737) available through March 12, 2026. ImmuCell expects no change to preliminary sales disclosed January 8, 2026 and plans to file its Form 10-K on or before March 31, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – ICCC
In the Feb 18 session, ICCC gained 3.85%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings date set | Neutral | -3.3% | Announced Q3 2025 results release date and conference call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date news saw a negative -3.33% move despite neutral scheduling content, suggesting a tendency for modest selling into these announcements.
Over recent months, ImmuCell has reported shifting dynamics between its First Defense® and Re-Tain® programs, including preliminary Q4 and FY 2025 sales, an FDA Incomplete Letter for Re-Tain®, and a strategic refocus toward First Defense®. Earlier, Q3 2025 earnings showed improved margins and a swing to nine‑month net income. The prior earnings date release on Nov 6, 2025 simply set the schedule for Q3 results and reaffirmed preliminary sales. Today’s announcement similarly schedules release of full Q4 and FY 2025 unaudited results and related calls.
Key Terms
form 10-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET
PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026.
The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 12, 2026 at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.
The Company anticipates no change to the preliminary sales results for the quarter and year ended December 31, 2025 that were disclosed on January 8, 2026. The Company expects to file its Annual Report on Form 10-K on or before Tuesday, March 31, 2026.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@immucell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com |
